Curated News
By: NewsRamp Editorial Staff
May 08, 2026
DrugScreens.com Spotlights SAFElife Drug Tests with Fentanyl & EtG Detection
TLDR
- DrugScreens.com's SAFElife lineup offers B2B buyers fentanyl and EtG detection, giving them a compliance advantage over competitors.
- SAFElife includes CLIA-waived urine cups, dip cards, and oral fluid kits with FUO and E&I classifications for workplace testing.
- By enabling accurate fentanyl and EtG detection, SAFElife helps employers ensure safer workplaces and healthier communities.
- SAFElife urine cups feature tamper-resistant design and fast results, ideal for high-volume onboarding and post-incident screening.
Impact - Why it Matters
This news matters because fentanyl and EtG detection are increasingly critical in workplace and clinical drug testing. Fentanyl, a potent opioid, is a major driver of overdose deaths, while EtG detects recent alcohol use. Employers and program administrators need reliable tests to ensure safety and compliance. DrugScreens.com's SAFElife lineup offers flexible, CLIA-waived options that simplify procurement and reduce regulatory burden, helping organizations quickly implement or upgrade their testing programs. For safety-sensitive industries, having both FUO and E&I classifications from one supplier streamlines operations and ensures legal defensibility.
Summary
DrugScreens.com has announced that the SAFElife drug test lineup is its featured brand for May, highlighting a product range that includes CLIA-waived urine cups, FUO urine cups with fentanyl and EtG detection, and oral fluid collection options. The spotlight reflects ongoing demand from B2B customers requiring accurate, timely results across workplace and clinical testing programs. The SAFElife line has been available since October, and this month-long feature gives procurement teams, HR professionals, and safety officers a concentrated opportunity to evaluate the full catalog.
The featured SAFElife products are organized into three categories. The CLIA-waived urine cups and FUO urine cups are designed for broad panel coverage, including detection for fentanyl and EtG—two substances that many standard panels have historically not included. Because these cups carry CLIA-waived status, they can be administered across non-laboratory settings without additional regulatory burden. The second category includes CLIA-waived dip cards, offering a flexible format with the same regulatory classification. The third category covers saliva drug test kits, available in Forensic Use Only (FUO) and Employment and Insurance (E&I) classifications. Notably, the saliva drug test kits do not include fentanyl detection, a distinction DrugScreens.com communicates to buyers.
The SAFElife drug test lineup is positioned exclusively for B2B buyers in the continental United States. Staffing firms, safety-sensitive employers, and clinical programs have been primary customer segments. For safety-sensitive industries, the distinction between FUO and E&I classifications is material. FUO products suit legal or investigative proceedings, while E&I products are for workplace screening tied to hiring or insurance. DrugScreens.com carries multiple brands to match the right test to the situation. The urine cups feature tamper-resistant designs and fast result timelines, reducing wait periods during onboarding or post-incident testing. The CLIA-waived urine cups have been adopted by clinical programs where regulatory compliance is a baseline requirement.
Source Statement
This curated news summary relied on content disributed by Press Services. Read the original source here, DrugScreens.com Spotlights SAFElife Drug Tests with Fentanyl & EtG Detection
